While anti-tumor immunity is a concerted effort of both the innate and adaptive immune systems, much of the attention is focused on the activity of CD8+ T cells specific to tumor cell-expressed mutant peptides (neoantigens). This evidence concerns the gene CD8A and neoplasm.